A significant reduction in the primary composite endpoint of CV death or worsening HF was reached with dapagliflozin in HF patients with LVEF >40% in the DELIVER phase III trial.
A secondary analysis of the EMPEROR-Preserved shows that empagliflozin reduces the primary outcome regardless of background mineralocorticoid receptor antagonists (MRA) therapy. Reduction of total HF hospitalization was more pronounced in MRA nonusers.
Omega-3 fatty acids have a beneficial effect on the number of HF hospitalizations in people with T2DM, especially in black people with T2DM.
ACC 2022 A randomized trial showed that a EHR-based alert led to higher rates of guideline-directed medical therapy (GDMT) prescription for patients with HFrEF compared with usual care.
The PROMINENT study, which investigated whether pemafibrate could reduce CV outcomes by reducing triglycerides in patients with T2DM, will be stopped early.
ACC 2022 A subanalysis of FIDELITY shows that the nonsteroidal MRA finerenone resulted in CV and kidney benefits in both primary and secondary prevention groups in a patient population with CKD and T2DM.
ACC 2022 This analysis showed that treatment with empagliflozin in patients with acute HF resulted in clinical benefit, regardless of symptomatic impairment at baseline, and improved symptoms, physical function and quality of life.
Translating trial results and recommendations from guidelines to individual patients can be challenging. Jan Westerink shares the findings of a study on the calculation of individual absolute benefit with semaglutide in patients with T2DM.
Using the DIAL model and pooled data from SUSTAIN 6 and PIONEER 6, a study shows that treatment with semaglutide is associated with a wide distribution in the gain in life-years free of CVD, that was dependent on baseline CVD risk and age at treatment initiation.
The Independent Data Monitoring Committee of the EMPA-KIDNEY trial has recommended to stop the trial early due to positive efficacy. The EMPA-KIDNEY trial evaluates the effect of empagliflozin in adults with CKD.
Empagliflozin has received approval from the European Commission for the treatment of symptomatic chronic HF across the full spectrum of LVEF.
This meta-analysis estimated and compared the effects of combinations of different pharmacological therapies for HFrEF.